Fosun Pharma plans Rp60bn Indian arm spin-off

By Jonathan Breen
13 Jul 2020

Gland Pharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, has filed preliminary IPO documents with India’s securities regulator for a listing.

Hong Kong-listed Shanghai Fosun has won approval for the spin-off from the city’s bourse, according to a joint filing with Fosun International on Friday night. The listing is expected to raise around Rp55bn ($731.6m) to Rp60bn, according to a source close to the deal.

Hyderabad-based Gland Pharma ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial